Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02014376 · ClinicalTrials.gov registry record · Phase 2

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

A Phase 2 study of Epidermolysis Bullosa, sponsored by Scioderm.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
7
Study locations

NCT02014376 is a Phase 2 study of Epidermolysis Bullosa that has completed, run by Scioderm. The registered enrollment target is 48 participants, above the 15-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (220% higher). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02014376, a Phase 2 study of Epidermolysis Bullosa, has completed, sponsored by Scioderm.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study was to assess whether the topical use of SD-101 cream (3% or 6%) was effective in treating wounds in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa (EB).

Conditions Studied

Epidermolysis Bullosa

Interventions

  • DRUG SD-101 dermal cream (3%)
  • DRUG SD-101 Dermal Cream (6%)
  • DRUG Vehicle (SD-101 0%)

Study Locations (7)

California

  • - Palo Alto

Illinois

  • - Chicago

Missouri

  • - St Louis

New Jersey

  • - Hackensack

North Carolina

  • - Chapel Hill

Texas

  • - San Antonio

Washington

  • - Seattle

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2014-01-06
Est. Completion 2014-06-24
Phase Phase 2

Sponsor

Scioderm

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02014376

The ClinicalTrials.gov registry entry for NCT02014376 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 15-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (220% higher). The listed sponsor is Scioderm, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Epidermolysis Bullosa appearing as the primary indexed condition, and to 3 interventions - of which SD-101 dermal cream (3%) is the first listed.

NCT02014376 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Illinois, Missouri.

Frequently Asked Questions

What is clinical trial NCT02014376 about?

NCT02014376 is a clinical study titled "Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa". The purpose of this study was to assess whether the topical use of SD-101 cream (3% or 6%) was effective in treating wounds in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa (EB).

What is the current status of trial NCT02014376?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2014-01-06. Estimated completion is 2014-06-24.

What conditions does trial NCT02014376 study?

This clinical trial studies the following conditions: Epidermolysis Bullosa.

What interventions are being tested in trial NCT02014376?

The interventions under investigation include: SD-101 dermal cream (3%) (DRUG), SD-101 Dermal Cream (6%) (DRUG), Vehicle (SD-101 0%) (DRUG).

Who is sponsoring clinical trial NCT02014376?

This trial is sponsored by Scioderm, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02014376 being conducted?

This trial has 7 study locations across California, Illinois, Missouri, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Epidermolysis Bullosa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Epidermolysis Bullosa

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.